Michael Offin Selected Research

Michael Offin Research Topics

Disease

34	Neoplasms (Cancer) 04/2024 - 01/2017
27	Lung Neoplasms (Lung Cancer) 02/2024 - 01/2017
9	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2024 - 01/2019
5	Adenocarcinoma of Lung 12/2021 - 08/2019
4	Mesothelioma 04/2024 - 12/2022
3	Disease Progression 11/2023 - 01/2020
3	Neoplasm Metastasis (Metastasis) 08/2022 - 01/2020
3	Brain Neoplasms (Brain Tumor) 01/2020 - 10/2018
2	Melanoma (Melanoma, Malignant) 02/2024 - 01/2023
2	Malignant Mesothelioma 12/2023 - 01/2021
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 12/2021
2	Carcinogenesis 01/2021 - 01/2021
1	Hypoxia (Hypoxemia) 04/2024
1	Fatigue 02/2024
1	Vomiting 02/2024
1	Nausea 02/2024
1	Diarrhea 02/2024
1	Skin Neoplasms (Skin Cancer) 02/2024
1	Fever (Fevers) 03/2022
1	Breast Neoplasms (Breast Cancer) 01/2021
1	B-Cell Leukemia (Leukemia, B Cell) 01/2021
1	Radiation Pneumonitis 01/2021
1	Lymphoma (Lymphomas) 01/2021
1	Leukemia 10/2018
1	Thrombocytopenia (Thrombopenia) 01/2018
1	Wounds and Injuries (Trauma) 03/2015
1	Critical Illness (Critically Ill) 03/2015
1	Heart Arrest (Cardiac Arrest) 03/2015
1	Lung Injury 08/2011
1	Contusions 08/2011

Drug/Important Bio-Agent (IBA)

8	Tyrosine Kinase InhibitorsIBA 01/2021 - 01/2018
5	DNA (Deoxyribonucleic Acid)IBA 02/2024 - 08/2019
5	durvalumabIBA 01/2023 - 01/2020
4	Biomarkers (Surrogate Marker)IBA 11/2023 - 01/2019
4	Proteins (Proteins, Gene)FDA Link 12/2021 - 01/2018
4	RNA (Ribonucleic Acid)IBA 01/2021 - 08/2019
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2023 - 01/2020
3	Circulating Tumor DNAIBA 11/2022 - 01/2017
3	Cell-Free Nucleic AcidsIBA 08/2022 - 11/2019
3	osimertinibIBA 10/2021 - 01/2018
3	Ado-Trastuzumab EmtansineIBA 01/2020 - 01/2018
2	binimetinibIBA 02/2024 - 01/2023
2	encorafenibIBA 02/2024 - 01/2023
2	Phosphotransferases (Kinase)IBA 01/2022 - 08/2019
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020 - 10/2018
2	Immunoconjugates (Immunoconjugate)IBA 01/2020 - 01/2018
2	ErbB Receptors (EGF Receptor)IBA 12/2019 - 01/2019
2	human ERBB2 proteinIBA 12/2019 - 01/2018
1	3- (3,5- dichlorophenyl)- 1- methyl- 2,5- pyrrolidinedione (DPMS)IBA 04/2024
1	AsbestosIBA 04/2024
1	Oxygen (Dioxygen)IBA 04/2024
1	Pemetrexed (MTA)FDA Link 11/2023
1	Protein-Arginine N-Methyltransferases (Methyltransferase, Protein Arginine)IBA 11/2023
1	pembrolizumabIBA 01/2023
1	B7-H1 AntigenIBA 01/2023
1	PlatinumIBA 11/2022
1	Interleukin-6 (Interleukin 6)IBA 03/2022
1	Chimeric Antigen ReceptorsIBA 03/2022
1	MesothelinIBA 03/2022
1	selinexorIBA 01/2022
1	Cisplatin (Platino)FDA LinkGeneric 01/2022
1	ParaffinIBA 01/2022
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2022
1	Formaldehyde (Formol)FDA Link 01/2022
1	Surface Antigens (Surface Antigen)IBA 01/2021
1	MTOR InhibitorsIBA 01/2021
1	LigandsIBA 01/2021
1	Sirolimus (Rapamycin)FDA Link 01/2021
1	cyclo(Arg-Pro) (CI 4)IBA 01/2021
1	CrizotinibIBA 01/2020
1	Cytotoxins (Cytolysins)IBA 01/2020
1	trastuzumab deruxtecanIBA 01/2020
1	ORALIT (ORS)IBA 12/2019
1	Peptides (Polypeptides)IBA 10/2019
1	Cytidine DeaminaseIBA 10/2019
1	APOBEC-1 DeaminaseIBA 10/2019
1	Co-Repressor ProteinsIBA 10/2019
1	Codon (Codons)IBA 01/2019
1	Messenger RNA (mRNA)IBA 01/2019
1	Immune Checkpoint InhibitorsIBA 01/2019
1	Core Binding Factors (Core-Binding Factor)IBA 10/2018
1	Sunitinib (Sutent)FDA Link 10/2018
1	cabozantinibIBA 10/2018
1	vandetanib (ZD6474)IBA 10/2018
1	Transaminases (Aminotransferases)IBA 01/2018
1	entrectinibIBA 01/2018
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 08/2011

Therapy/Procedure

20	Therapeutics 11/2023 - 01/2017
5	Radiotherapy 02/2024 - 01/2021
2	Drug Therapy (Chemotherapy) 11/2022 - 01/2022
2	Immunotherapy 01/2019 - 01/2019
1	Cryosurgery 04/2024
1	Continuity of Patient Care 08/2022
1	Adjuvant Chemotherapy 08/2021
1	Precision Medicine 01/2017
1	Resuscitation 03/2015